Pular para o conteúdo principal
Ranking Invest

CGEM - Cullinan Oncology, Inc.

Segmento: HealthcareCullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 312.58 Mi
Valor de Mercado
$ 1.32 Bi
Desconto (AV)-523.5%
IVR
-0.24A companhia vale -0,24 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.49O valuation alternativo equivale a -49% do valor de mercado da companhia.
MLL
-0.49O lucro líquido dos controladores em 16 trimestres equivale a -49% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 321.75 Mi

Dívida Líquida

-$ 78.64 Mi

L4T

-$ 204.69 Mi

Indicadores Básicos

ROE

-63.62%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

B0.15

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

F-7.83

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.24

DIV/L4T

0.38

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.